H Kouhara
Overview
Explore the profile of H Kouhara including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
729
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Painless thyroiditis occurring during post-menopausal period, following remission of Graves' disease
Kasayama S, Kitamura T, Inaba M, Otsuki M, Asanuma N, Kouhara H
J Endocrinol Invest
. 2008 Feb;
31(1):92-3.
PMID: 18296912
No abstract available.
2.
Goya K, Kitamura T, Inaba M, Otsuki M, Yamamoto H, Kurebayashi S, et al.
Metabolism
. 2003 Oct;
52(10):1302-6.
PMID: 14564682
Atherosclerotic vascular diseases are frequently associated with diabetes mellitus. There has been increasing evidence showing that the atherosclerotic diseases in diabetic patients are distinct from diabetic microvascular complications as to...
3.
Hirose T, Miyashita Y, Takagi M, Sumitani S, Kouhara H, Kasayama S
Diabetes Res Clin Pract
. 2001 Sep;
54(1):9-15.
PMID: 11532325
In this study, we characterized type 2 diabetic patients responding well to the alpha-glucosidase inhibitor voglibose administration as an adjunct to sulfonylurea treatment. Thirty-three type 2 diabetic patients were enrolled...
4.
Otsuki M, Saito H, Xu X, Sumitani S, Kouhara H, Kurabayashi M, et al.
Atherosclerosis
. 2001 Aug;
158(1):121-8.
PMID: 11500182
Cilostazol is a specific inhibitor of cAMP phosphodiesterase, which is used for treatment of ischemic symptoms of peripheral vascular disease. Although cilostazol has antiplatelet and vasodilator properties, its effect on...
5.
Xu X, Otsuki M, Saito H, Sumitani S, Yamamoto H, Asanuma N, et al.
Endocrinology
. 2001 Jul;
142(8):3332-9.
PMID: 11459775
The antiinflammatory action of glucocorticoids is mediated partly by the inhibition of the expression of several cytokines and adhesion molecules. Some activators for nuclear receptors other than the GR have...
6.
Hadari Y, Gotoh N, Kouhara H, Lax I, Schlessinger J
Proc Natl Acad Sci U S A
. 2001 Jul;
98(15):8578-83.
PMID: 11447289
The docking protein FRS2 alpha has been implicated as a mediator of signaling via fibroblast growth factor receptors (FGFRs). We have demonstrated that targeted disruption of FRS2 alpha gene causes...
7.
Otsuki M, Kasayama S, Yamamoto H, Saito H, Sumitani S, Kouhara H, et al.
Clin Endocrinol (Oxf)
. 2001 Jun;
54(6):791-6.
PMID: 11422114
Objective: Acromegalic patients have increased mortality from vascular diseases. Although atherosclerotic risk factors such as hypertension, diabetes mellitus and dyslipoproteinaemia are highly associated with acromegaly, the prevalence of premature atherosclerosis...
8.
Otsuki M, Saito H, Xu X, Sumitani S, Kouhara H, Kishimoto T, et al.
Arterioscler Thromb Vasc Biol
. 2001 Feb;
21(2):243-8.
PMID: 11156860
-It has been shown that ovarian steroid hormones can reduce the incidence of cardiovascular disease in postmenopausal women. As hormone replacement therapy for postmenopausal women, progestins are added to estrogens...
9.
Kasayama S, Otsuki M, Takagi M, Saito H, Sumitani S, Kouhara H, et al.
Clin Endocrinol (Oxf)
. 2000 May;
52(5):549-55.
PMID: 10792333
Objective: Abnormal glucose tolerance is often demonstrated in acromegalic patients. Although insulin resistance is a common feature of acromegaly, it remains unclear whether the extent of insulin resistance per se...
10.
Hadari Y, Kouhara H, Lax I, Schlessinger J
Mol Cell Biol
. 1998 Jun;
18(7):3966-73.
PMID: 9632781
FRS2 is a lipid-anchored docking protein that plays an important role in linking fibroblast growth factor (FGF) and nerve growth factor receptors with the Ras/mitogen-activated protein (MAP) kinase signaling pathway....